Podcast Episode 84: Managing Anxiety with PD

PD Library thumbnail

The Parkinson’s Outcomes Project (POP) is the largest-ever clinical study of people with Parkinson’s disease (PD). Since the beginning of this groundbreaking initiative in 2009, Parkinson’s Foundation Centers of Excellence have been tracking and monitoring the care of more than 13,000 people in five countries with all stages of PD. The goal is to find the most effective therapies, study their benefits, and determine the best candidates for each treatment.

One of the findings of POP is that anxiety is a major factor affecting the overall health of people with PD. Worry about a health condition is normal, but when it becomes constant feelings of worry or nervousness beyond what is understandable, it may be anxiety, a mental health condition. Anxiety is not just a reaction to a diagnosis of PD or the daily stresses that accompany it but is also an integral part of the disease caused by changes in brain chemistry. It may even predate the diagnosis.

As many as 40 percent of people with PD will experience some form of anxiety, such as generalized anxiety disorder, anxiety attacks, social avoidance, or obsessive-compulsive disorder. Fortunately, mental health professionals can help by providing effective talk and, when appropriate, drug therapies. In this episode, clinical psychologist Roseanne Dobkin, PhD, Professor of Psychiatry at Rutgers University in New Jersey, discusses the difference between reasonable worry and problematic anxiety and elucidates some of the ways mental health professionals can help when feelings become distressing or all consuming, interfering with day to day life and activities.

Download This Episode

Read Episode Transcript Here

Related Resources

About This Episode

Released: June 30, 2020

DobkinRoseanne Dobkin, PhD

Roseanne Dobkin is a licensed clinical psychologist and Professor of Psychiatry at Rutgers University with a well-established clinical research program in the mental health aspects of Parkinson’s disease (PD).

Key objectives of her research program include 1) improving the recognition, assessment and treatment of the neuropsychiatric complications of PD, including cognition, depression, anxiety, and sleep, 2) advancing the understanding of the complex interaction between the motor and non-motor symptoms of PD and the influence of this interaction on course and progression of PD, and 3) utilizing applications of telemedicine to leverage access to informed mental health care for all members of the PD community. To date, her PD research has been funded by the National Institutes of Health, the Patterson Trust Awards Program in Clinical Research, the Michael J. Fox Foundation for Parkinson’s Research, the Parkinson’s Unity Walk, the Parkinson’s Foundation, and the Health Services Research and Development Division (HSR&D; Merit Award) of the Veteran Affairs Administration.

This episode is supported by a grant from Genentech, a member of the Roche Group.


Want More?

Don't forget to subscribe! There are many ways to listen: Apple PodcastsGoogle PlayTuneIn (Amazon Echo), Spotify or RSS Feed. (Need help subscribing? See our quick guide.)

For all of our Substantial Matters podcast episodes, visit parkinson.org/podcast.


Sign Up for Our E-Newsletter

Get the latest news about PD research, resources and community initiatives – straight to your inbox.

Please enter a valid email

Skip step

Invalid year format. Eg: 2020
Skip step
Zip code is required for chapter communications
Skip step

*Please note that not all content is available in both languages. If you are interested in receiving Spanish communications, we recommend selecting “both" to stay best informed on the Foundation's work and the latest in PD news.

Skip step

Thanks for Signing Up

We are proud to have you as a part of our community. To ensure you receive the latest Parkinson’s news, research updates and more, please check your email for a message from us. If you do not see our email, it may be in your spam folder. Just mark as “not spam” and you should receive our emails as expected.

mail icon

Subscribe here to get the latest news on treatments, research and other updates.